Skip to main content

Drug Interactions between belumosudil and Zegerid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

omeprazole belumosudil

Applies to: Zegerid (omeprazole / sodium bicarbonate) and belumosudil

Omeprazole may decrease the blood levels of belumosudil, which may reduce its effectiveness in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment to safely use both medications. Contact your doctor if your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

sodium bicarbonate belumosudil

Applies to: Zegerid (omeprazole / sodium bicarbonate) and belumosudil

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with gastric acid-reducing agents other than proton pump inhibitors (PPIs) may reduce the oral bioavailability of belumosudil. The mechanism of interaction has not been established. Concomitant use of the PPI rabeprazole decreased belumosudil peak plasma concentration (Cmax) and systemic exposure (AUC) by 87% and 80%, respectively, while coadministration of omeprazole decreased belumosudil Cmax and AUC by 68% and 47%, respectively, in healthy subjects. Data for other gastric acid-reducing agents are not available.

MANAGEMENT: The potential for diminished pharmacologic effects of belumosudil should be considered during coadministration with gastric acid-reducing agents other than PPIs. Other authorities recommend having a dosing interval of at least 12 hours between the latter and belumosudil (GB).

References

  1. (2024) "Product Information. Rezurock (belumosudil)." Sanofi
  2. (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023

Drug and food interactions

Moderate

belumosudil food

Applies to: belumosudil

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Administration with food increases the oral bioavailability of belumosudil. The mechanism has not been described. Administration of belumosudil (200 mg single oral dose) in healthy subjects, with a fatty and calorie-rich meal (approximately half of the calories were contained in the fat) increased the mean belumosudil peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 120% and 100%, respectively, compared to administration under fasting conditions. The time to reach peak concentration (Tmax) was delayed by 30 minutes. Administration of oral belumosudil 200 mg once daily with food in patients with chronic graft-versus-host disease (chronic GVHD) lead to steady-state concentrations of the drug with an accumulation ration of 1.4.

MANAGEMENT: To ensure maximal oral absorption, belumosudil should be administered with a meal, every day at the same time.

References

  1. (2024) "Product Information. Rezurock (belumosudil)." Sanofi
  2. (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer